Teachers Retirement System of The State of Kentucky Purchases 18,135 Shares of Pfizer Inc. (NYSE:PFE)

Teachers Retirement System of The State of Kentucky grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 437,753 shares of the biopharmaceutical company's stock after acquiring an additional 18,135 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Pfizer were worth $11,093,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. purchased a new position in Pfizer during the 1st quarter valued at $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer in the 4th quarter worth $30,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.46 on Monday. The firm's 50 day moving average price is $24.07 and its 200-day moving average price is $24.71. The stock has a market capitalization of $139.06 billion, a PE ratio of 17.72, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the business earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.03%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Bank of America increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Morgan Stanley raised their price objective on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets reduced their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.